Negar Khazan
Overview
Explore the profile of Negar Khazan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
73
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kim K, Khazan N, McDowell J, Snyder C, Miller J, Singh R, et al.
PLoS One
. 2024 Dec;
19(12):e0314564.
PMID: 39621651
Ovarian cancer is the leading cause of death among gynecologic malignancies. Despite recent advancements in targeted therapies such as PARP inhibitors, recurrence is common and frequently resistant to existing therapies....
2.
Ciccioli M, Kim K, Khazan N, Khoury J, Cooke M, Miller M, et al.
J Exp Clin Cancer Res
. 2024 Aug;
43(1):240.
PMID: 39169412
Circulating Tumor Cells (CTCs) may serve as a non-invasive source of tumor material to investigate an individual's disease in real-time. The Parsortix PC1 System, the first FDA-cleared medical device for...
3.
Ghaffari P, Yousefi M, Aznab M, Khazan N, Yaghmaie M, Bashash D, et al.
Cell J
. 2024 Jul;
26(5):293-308.
PMID: 39066594
Objective: Despite the advances in treatment, breast cancer (BC) remains a major cause of death in women. This study aims to evaluate the prognostic significance of detecting circulating tumor cells...
4.
Kim K, Khazan N, Rowswell-Turner R, Singh R, Moore T, Strawderman M, et al.
Cancers (Basel)
. 2024 Mar;
16(5).
PMID: 38473335
Forchlorfenuron (FCF) is a widely used plant cytokinin that enhances fruit quality and size in agriculture. It also serves as a crucial pharmacological tool for the inhibition of septins. However,...
5.
Templeman A, Miller M, Cooke M, OShannessy D, Gurung Y, Pereira T, et al.
J Circ Biomark
. 2023 Aug;
12:26-33.
PMID: 37601320
Introduction: The Parsortix PC1 system, Food and Drug Administration (FDA) cleared for use in metastatic breast cancer (MBC) patients, is an epitope-independent microfluidic device for the capture and harvest of...
6.
Khazan N, Quarato E, Singh N, Snyder C, Moore T, Miller J, et al.
Cancers (Basel)
. 2023 Jul;
15(13).
PMID: 37444542
Small-molecule inhibitors of PD-L1 are postulated to control immune evasion in tumors similar to antibodies that target the PD-L1/PD-1 immune checkpoint axis. However, the identity of targetable PD-L1 inducers is...
7.
Cohen E, Jayachandran G, Moore R, Cristofanilli M, Lang J, Khoury J, et al.
Cancers (Basel)
. 2022 Nov;
14(21).
PMID: 36358657
Circulating tumor cells (CTCs) captured from the blood of cancer patients may serve as a surrogate source of tumor material that can be obtained via a venipuncture (also known as...
8.
Moore R, Khazan N, Coulter M, Singh R, Miller M, Sivagnanalingam U, et al.
Obstet Gynecol
. 2022 Sep;
140(4):631-642.
PMID: 36075062
Objective: To evaluate the detection of malignancy in women with a pelvic mass by using multiplexed gene expression analysis of cells captured from peripheral blood. Methods: This was an IRB-approved,...
9.
Khazan N, Kim K, Hansen J, Singh N, Moore T, Snyder C, et al.
J Med Chem
. 2022 Apr;
65(8):6039-6055.
PMID: 35404047
Vitamin-D receptor (VDR) mRNA is overexpressed in neuroblastoma and carcinomas of lung, pancreas, and ovaries and predicts poor prognoses. VDR antagonists may be able to inhibit tumors that overexpress VDR....
10.
Rowswell-Turner R, Singh R, Urh A, Yano N, Kim K, Khazan N, et al.
J Immunol
. 2021 Apr;
206(10):2478-2488.
PMID: 33903172
Ovarian cancer is a highly fatal malignancy characterized by early chemotherapy responsiveness but the eventual development of resistance. Immune targeting therapies are changing treatment paradigms for numerous cancer types but...